Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06853964 · ClinicalTrials.gov registry record

Retrospective Study of AlloMend Acellular Dermal Matrix (ADM) Allograft and Pre-Pectoral Breast Reconstruction

A clinical trial of Pre-Pectoral Breast Reconstruction Following Mastectomy, sponsored by AlloSource.

Active
Registry status
100
Enrollment target
1
Study location

NCT06853964 is a study of Pre-Pectoral Breast Reconstruction Following Mastectomy that is active but no longer recruiting, run by AlloSource. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06853964, a study of Pre-Pectoral Breast Reconstruction Following Mastectomy, is active but no longer recruiting, sponsored by AlloSource.

ACTIVE NOT RECRUITING
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

This retrospective, single-site study will provide information regarding the efficiency of AlloMend® Acellular Dermal Matrix allograft in Pre-Pectoral Breast Reconstruction surgery following a single or double mastectomy.

Interventions

  • OTHER AlloMend® Acellular Dermal Matrix allograft

Study Locations (1)

Nevada

  • Janiga MDs Plastic Surgery and Cosmetic Center - Reno

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-01-27
Est. Completion 2026-05-31

Sponsor

AlloSource

7 total trials

What the Registry Record Tells You About NCT06853964

The ClinicalTrials.gov registry entry for NCT06853964 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AlloSource, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pre-Pectoral Breast Reconstruction Following Mastectomy appearing as the primary indexed condition, and to 1 intervention - of which AlloMend® Acellular Dermal Matrix allograft is the first listed.

NCT06853964 reports 1 study location spanning 1 distinct geographic area - top geographies include Nevada.

Frequently Asked Questions

What is clinical trial NCT06853964 about?

NCT06853964 is a clinical study titled "Retrospective Study of AlloMend Acellular Dermal Matrix (ADM) Allograft and Pre-Pectoral Breast Reconstruction". This retrospective, single-site study will provide information regarding the efficiency of AlloMend® Acellular Dermal Matrix allograft in Pre-Pectoral Breast Reconstruction surgery following a single or double mastectomy.

What is the current status of trial NCT06853964?

This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2025-01-27. Estimated completion is 2026-05-31.

What conditions does trial NCT06853964 study?

This clinical trial studies the following conditions: Pre-Pectoral Breast Reconstruction Following Mastectomy.

What interventions are being tested in trial NCT06853964?

The interventions under investigation include: AlloMend® Acellular Dermal Matrix allograft (OTHER).

Who is sponsoring clinical trial NCT06853964?

This trial is sponsored by AlloSource, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06853964 being conducted?

This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.